Interference with in vivo growth and metastasis of prostate adenocarcinoma (PA-III) by ICRF-159.

Abstract

Rat prostate adenocarcinoma III (PA III) cells metastasize spontaneously from extravascular implant sites through ipsilateral lymphatic channels to the lungs in which they develop as distinct expanding foci of tumors. ICRF-159 (30 + 60 mg/kg body weight) was administered to rats with PA-III cells at daily intervals from day 0 to 2 weeks (5 days/week). When the rats were examined after 35 and 40 days, the drug treatment caused a significant suppression of the primary tumor and of metastatic dissemination. When the treatment schedule with ICRF-159 was delayed to day 18 in rats with metastasizing PA III cells, the progress of metastasis was thereafter interrupted or retarded significantly. Rats with PA II cells which metastasize in fulminant pattern through lymphatic and blood channels to multiple target organs were administered ICRF-159 (60 mg/kg body weight) from day 0 for over 2 weeks. They did with disseminated tumors within days after cessation of treatments.

• Authors: M Pollard, G R Burleson, P H Luckert
• Journal: The Prostate (Prostate) Vol. 2 Issue 1 Pg. 1-9 ( 1981) ISSN: 0270-4137 [Print] United States
• PMID: 7279810 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Piperazines
• Razoxane

Topics

• Adenocarcinoma (drug therapy, physiopathology)
• Animals
• Cell Division (drug effects)
• Lymph Nodes (drug effects, physiopathology)
• Lymphatic Metastasis
• Male
• Neoplasm Metastasis
• Neoplasms, Experimental (drug therapy, physiopathology)
• Piperazines (therapeutic use)
• Prostatic Neoplasms (drug therapy, physiopathology)
• Rats
• Rats, Inbred Strains
• Razoxane (therapeutic use)